Open Access
Open access
volume 28 issue 2 pages 838

Imidazole: Synthesis, Functionalization and Physicochemical Properties of a Privileged Structure in Medicinal Chemistry

Publication typeJournal Article
Publication date2023-01-13
scimago Q1
wos Q2
SJR0.865
CiteScore8.6
Impact factor4.6
ISSN14203049
Organic Chemistry
Drug Discovery
Physical and Theoretical Chemistry
Pharmaceutical Science
Molecular Medicine
Analytical Chemistry
Chemistry (miscellaneous)
Abstract

Imidazole was first synthesized by Heinrich Debus in 1858 and was obtained by the reaction of glyoxal and formaldehyde in ammonia, initially called glyoxaline. The current literature provides much information about the synthesis, functionalization, physicochemical characteristics and biological role of imidazole. Imidazole is a structure that, despite being small, has a unique chemical complexity. It is a nucleus that is very practical and versatile in its construction/functionalization and can be considered a rich source of chemical diversity. Imidazole acts in extremely important processes for the maintenance of living organisms, such as catalysis in enzymatic processes. Imidazole-based compounds with antibacterial, anti-inflammatory, antidiabetic, antiparasitic, antituberculosis, antifungal, antioxidant, antitumor, antimalarial, anticancer, antidepressant and many others make up the therapeutic arsenal and new bioactive compounds proposed in the most diverse works. The interest and importance of imidazole-containing analogs in the field of medicinal chemistry is remarkable, and the understanding from the development of the first blockbuster drug cimetidine explores all the chemical and biological concepts of imidazole in the context of research and development of new drugs.

Found 
Found 

Top-30

Journals

1
2
3
4
5
ChemistrySelect
5 publications, 4.55%
Scientific Reports
5 publications, 4.55%
Journal of Molecular Structure
5 publications, 4.55%
Pharmaceutics
4 publications, 3.64%
Molecules
4 publications, 3.64%
Chemistry
2 publications, 1.82%
Chemistry - A European Journal
2 publications, 1.82%
Current Organic Chemistry
2 publications, 1.82%
Organic and Biomolecular Chemistry
2 publications, 1.82%
Polyhedron
2 publications, 1.82%
Journal of Organic Chemistry
2 publications, 1.82%
Synthetic Communications
2 publications, 1.82%
Crystal Growth and Design
1 publication, 0.91%
Plants
1 publication, 0.91%
MolBank
1 publication, 0.91%
Arabian Journal of Chemistry
1 publication, 0.91%
Antioxidants
1 publication, 0.91%
International Journal of Biological Macromolecules
1 publication, 0.91%
Future Medicinal Chemistry
1 publication, 0.91%
Structural Chemistry
1 publication, 0.91%
Frontiers in Medicine
1 publication, 0.91%
Heliyon
1 publication, 0.91%
Algal Research
1 publication, 0.91%
Synthetic Metals
1 publication, 0.91%
Chemical Communications
1 publication, 0.91%
Mediators of Inflammation
1 publication, 0.91%
Bioorganic and Medicinal Chemistry
1 publication, 0.91%
Frontiers in Immunology
1 publication, 0.91%
Synthesis
1 publication, 0.91%
Chinese Journal of Chemistry
1 publication, 0.91%
1
2
3
4
5

Publishers

5
10
15
20
25
30
Elsevier
27 publications, 24.55%
Wiley
19 publications, 17.27%
Springer Nature
16 publications, 14.55%
MDPI
14 publications, 12.73%
Royal Society of Chemistry (RSC)
8 publications, 7.27%
American Chemical Society (ACS)
5 publications, 4.55%
Taylor & Francis
4 publications, 3.64%
Bentham Science Publishers Ltd.
4 publications, 3.64%
Frontiers Media S.A.
3 publications, 2.73%
King Saud University
1 publication, 0.91%
Hindawi Limited
1 publication, 0.91%
Georg Thieme Verlag KG
1 publication, 0.91%
Shanghai Institute of Organic Chemistry
1 publication, 0.91%
International Union of Crystallography (IUCr)
1 publication, 0.91%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.91%
Pleiades Publishing
1 publication, 0.91%
Turkish Chemical Society
1 publication, 0.91%
A and V Publications
1 publication, 0.91%
Ural Federal University
1 publication, 0.91%
5
10
15
20
25
30
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
110
Share
Cite this
GOST |
Cite this
GOST Copy
Tolomeu H. V. et al. Imidazole: Synthesis, Functionalization and Physicochemical Properties of a Privileged Structure in Medicinal Chemistry // Molecules. 2023. Vol. 28. No. 2. p. 838.
GOST all authors (up to 50) Copy
Tolomeu H. V., Fraga C. Imidazole: Synthesis, Functionalization and Physicochemical Properties of a Privileged Structure in Medicinal Chemistry // Molecules. 2023. Vol. 28. No. 2. p. 838.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.3390/molecules28020838
UR - https://doi.org/10.3390/molecules28020838
TI - Imidazole: Synthesis, Functionalization and Physicochemical Properties of a Privileged Structure in Medicinal Chemistry
T2 - Molecules
AU - Tolomeu, Heber Victor
AU - Fraga, Carlos
PY - 2023
DA - 2023/01/13
PB - MDPI
SP - 838
IS - 2
VL - 28
PMID - 36677894
SN - 1420-3049
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2023_Tolomeu,
author = {Heber Victor Tolomeu and Carlos Fraga},
title = {Imidazole: Synthesis, Functionalization and Physicochemical Properties of a Privileged Structure in Medicinal Chemistry},
journal = {Molecules},
year = {2023},
volume = {28},
publisher = {MDPI},
month = {jan},
url = {https://doi.org/10.3390/molecules28020838},
number = {2},
pages = {838},
doi = {10.3390/molecules28020838}
}
MLA
Cite this
MLA Copy
Tolomeu, Heber Victor, et al. “Imidazole: Synthesis, Functionalization and Physicochemical Properties of a Privileged Structure in Medicinal Chemistry.” Molecules, vol. 28, no. 2, Jan. 2023, p. 838. https://doi.org/10.3390/molecules28020838.